MARKET

PRPO

PRPO

Precipio Inc
NASDAQ
6.15
-0.18
-2.84%
Opening 12:26 04/23 EDT
OPEN
6.29
PREV CLOSE
6.33
HIGH
6.29
LOW
6.06
VOLUME
3.46K
TURNOVER
0
52 WEEK HIGH
14.80
52 WEEK LOW
4.750
MARKET CAP
8.80M
P/E (TTM)
-1.3637
1D
5D
1M
3M
1Y
5Y
Weekly Report: what happened at PRPO last week (0415-0419)?
Weekly Report · 1d ago
Weekly Report: what happened at PRPO last week (0408-0412)?
Weekly Report · 04/15 12:09
Weekly Report: what happened at PRPO last week (0401-0405)?
Weekly Report · 04/08 12:15
PRPO Stock Earnings: Precipio Beats EPS, Misses Revenue for Q4 2023
Precipio reported earnings per share of 88 cents for the fourth quarter of 2023. The company reported revenue of $4.33 million. This was 11.65% worse than the analyst estimate for revenue. Precipio also reported results for the third quarter of 2018.
Investorplace · 04/01 14:53
Weekly Report: what happened at PRPO last week (0325-0329)?
Weekly Report · 04/01 12:12
Precipio Inc Schedules Year-End Shareholder Update Call
TipRanks · 03/26 20:53
Precipio Announces Year end 2023 Shareholder Update Call
Specialty cancer diagnostics company Precipio, Inc. Will be hosting its year end 2023 corporate update call on April 1st, 2024 at 5:00 PM ET. The call will include updates on all of the company's current core businesses.
Barchart · 03/25 16:00
Weekly Report: what happened at PRPO last week (0318-0322)?
Weekly Report · 03/25 12:15
More
About PRPO
Precipio, Inc. is a healthcare biotechnology company that is focused on cancer diagnostics. It develops and sells diagnostic products, reagents and services that improve the accuracy and efficiency of diagnostics, and lead to fewer misdiagnoses. The Company’s technologies include HemeScreen and IV-Cell. IV-Cell is a cell culture media that addresses the problem of diagnostic mistakes through the process of selective culturing. IV-Cell is a universal media that enables simultaneous culturing of all four hematopoietic cell lineages. Its technology enables testing to be completed in one rapid scanning process. The HemeScreen panels test for the presence of various mutations. In developing HemeScreen, it focused on improving the economics of providing blood cancer diagnostic tests and reducing laboratory technician time consumed in the testing process. The Company’s laboratory and research and development (R&D) facilities are located in New Haven, Connecticut and Omaha, Nebraska.

Webull offers Precipio Inc stock information, including NASDAQ: PRPO real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, PRPO stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading PRPO stock methods without spending real money on the virtual paper trading platform.